
6. A use of a compound represented by the following structural formula (I)




a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group; said compound is selected from the group wherein:
R_1 is H, R_2 is F or Cl and R_3 is H or CH_3;
R_1 is F, R_2 is F and R_3 is H;
R_1 is CH_3, R_2 is OCH_3 and R_3 is H;
R_1 is CH_3, R_2 is F and R_3 is H;
R_1 is CH_3, R_2 is H and R_3 is F;
R_1 is Cl, R_2 is H and R_3 is CH_3;
R_1 is OCF_3, R_2 is H or OCH_3 and R_3 is H and
R_1 is OCF_3, R_2 is H and R_3 is CH_3
in the manufacture of a medicament for inhibiting the replication of dengue virus(es) in a patient.

7. The use of a compound according to claim 6 further comprising an additional therapeutic agent.

8. The use of claim 7 wherein said additional therapeutic agent is another antiviral agent.

9. A use of a compound represented by the following structural formula (I)



a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group; said compound is selected from the group wherein:
R_1 is H, R_2 is F or Cl and R_3 is H or CH_3;
R_1 is F, R_2 is F and R_3 is H;
R_1 is CH_3, R_2 is OCH_3 and R_3 is H;
R_1 is CH_3, R_2 is F and R_3 is H;
R_1 is CH_3, R_2 is H and R_3 is F;
R_1 is Cl, R_2 is H and R_3 is CH_3;
R_1 is OCF_3, R_2 is H or OCH_3 and R_3 is H and

R_1 is OCF_3, R_2 is H and R_3 is CH_3
for inhibiting the replication of dengue virus(es) in a biological sample.